Inflammasome–mediated inflammatory disease treatment with β-hydroxybutyrate and similar compounds

• NLRP3 inflammasome activation is implicated in a number of diseases such as gout, atherosclerosis, type-2 diabetes, Alzheimers disease, multiple sclerosis, Muckle-Wells Syndrome (MWS), Familial Cold Autoinflammatory Syndrome (FCAS).
• The ketone body β-hydroxybutyrate (BHB) as well as g-hydroxybutyric acid (GHB) can inhibit NLRP3 inflammasome activation. BHB delivery in vivo reduced NLRP3 inflammasome-mediated Interleukin (IL)-1bsecretion, reversing phenotypes in animal models with gout, MWS, FCAS, and peritonitis.
• Intellectual property: US patent application pending
• Reference: Youm YH et al. (2015) Nat Med 21: 263-269